Cite
HARVARD Citation
Galanis, E. et al. (2019). A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer. 125 (21), pp. 3790-3800. [Online].